Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Viridian Therapeutics, Inc.DE

Get SEC filing alerts via email and in your feed for Viridian Therapeutics, Inc.DE

VRDN

Viridian Therapeutics, Inc.DE

About Viridian Therapeutics, Inc.DE

Viridian Therapeutics is a biopharmaceutical company developing innovative biologic medicines for serious and rare diseases, primarily focusing on thyroid eye disease (TED). Its pipeline includes monoclonal antibodies targeting IGF-1R and engineered FcRn inhibitors to improve efficacy, safety, and convenience. The company aims to address unmet medical needs, advance clinical trials globally, and secure regulatory approvals for differentiated therapies in autoimmune and ophthalmic conditions.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Viridian Therapeutics, Inc.DE

1
1
Viridian Therapeutics, Inc.DE Viridian Therapeutics Reports Q1 2026 Revenue Growth to $141,000, Net Loss Increases to $104.9 Million

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Viridian Therapeutics, Inc.DE Viridian Therapeutics Reports $342.6 Million Net Loss and $70.8 Million Revenue for 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Viridian Therapeutics, Inc.DE Viridian Therapeutics Reports $70.6M Revenue in Q3 2025, Net Loss Decreases to $34.6M

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Viridian Therapeutics, Inc.DE Viridian Therapeutics Reports $100.7 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Viridian Therapeutics, Inc.DE Viridian Therapeutics Reports Increased Losses of $86.9 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Viridian Therapeutics, Inc.DE Viridian Therapeutics Reports $269.9 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Viridian Therapeutics, Inc.DE Viridian Therapeutics Reports Increased Assets, Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments